Patients who present with hypertensive urgency or emergency require immediate attention to assess the severity of illness. Guidelines from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure are available but do little to address the management of acute elevations in blood pressure. Various treatment options, both old and new, exist to manage these patients in the emergency department. Decisions on therapy are patient specific and depend on the underlying cause of elevated blood pressure. This article sets out to describe specific patient presentations and reviews current available options in the management of hypertensive urgencies and emergencies.
American Heart Association. Number of adults in U.S. with high blood pressure rose in last decade. Available at: http://www.americanheart.org/presenter.jhtml?identifier=3024254. Accessed September 25, 2004.
4.
Chobanian AV, Barkis GL, Black HR, et al.The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
5.
Grossman E, Messerli FH, Grodzicki T, Kowey P.Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?JAMA. 1996;276:1328-1331.
6.
Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 2000;118:214-227.
7.
Cherney D, Straus S.Management of patients with hypertensive urgencies and emergencies. J Gen Intern Med. 2002;17:937-945.
8.
Bales A.Hypertensive crisis. how to tell if it’s an emergency or an urgency. Postgrad Med. 1999;105:119-126.
9.
Zampaglione B, Pascale C, Marchisio M, Cavallo-Perin P.Hypertensive urgencies and emergencies: prevalence and clinical presentation. Hypertension. 1996;27:144-147.
10.
The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-2446.
11.
Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens. 2001;14:1154-1167.
12.
Shea S, Misra D, Ehrlich MH, Field L, Francis CK. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med. 1992;327:776-781.
13.
Neal B, MacMahon S, Chapman N.Effects of ACE inhibitors, calcium antagonists, and other blood-pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;355:1955-1964.
14.
Lewington S, Clarke R, Qizilbash N, Petro R, Collins R.Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
15.
Castillo J, Leira R, Garcia M, Serena J, Blanco M, Davalos A.Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke. 2004;35:520-527.
16.
Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA. Blood pressure and clinical outcomes in the international stroke trial. Stroke. 2002;33:1315-1320.
17.
International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens. 2003;21:665-672.
18.
Rose J, Mayer S.Optimizing blood pressure in neurologic emergencies. Neurocritical Care. 2004;3:287-300.
19.
International Stroke Trial Collaborative Group. The International Stoke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet. 1997;349:1569-1581.
20.
Broderick JP, Hacke W.Treatment of acute ischemic stroke. Part II: neuroprotection and medical management. Circulation. 2002;106:1736-1740.
21.
Adams HP, Adams RJ, Brott T, et al.Guidelines for the early management of patients with ischemic stroke. Stroke. 2003;34:1056-1083.
22.
Cottrell JE, Patel K, Turndorf H, Ransohoff J.Intracranial pressure changes induced by sodium nitroprusside in patients with intracranial lesions. J Neurosurg. 1978;48:329-331.
23.
Varon J, Fromm R.Hypertensive crises: the need for urgent management. Postgrad Med. 1996;99:189-200.
24.
Grossman E, Ironi A, Messerli F.Comparative tolerability profile of hypertensive crisis treatments. Drug Saf. 1998;19:99-122.
25.
Elliott W.Hypertensive emergencies. Crit Care Clin. 2001;17:435-451.
26.
Prisant L, Carr A, Hawkins D.Treating hypertensive emergencies: controlled reduction of blood pressure and protection of target organs. Postgrad Med. 1993;93:92-110.
Shusterman N, Elliott W, White W.Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161-168.
29.
Lu JF, Nightingale CH. Magnesium sulfate in eclampsia and preeclampsia. Clin Pharmacokinet. 2000;38:305-314.
30.
Lew M, Klonis E.Emergency management of eclampsia and severe pre-eclampsia. Emerg Med. 2003;15:361-368.
31.
Longo SA, Dola CP, Pridjian G.Preeclampsia and eclampsia revisited. South Med J. 2003;96:891-899.
32.
Myers JE, Baker PN. Hypertensive diseases and eclampsia. Curr Opin Obstet Gynecol. 2002;14:119-125.
33.
Douglas KA, Redman CW. Eclampsia in the United Kingdom. Br Med J1994;309:1395-1399.
34.
The Eclampsia Trial Collaborative Group. Which anticonvulsant for woman with eclampsia? Evidence from the collaborative eclampsia trial. Lancet. 1995;345:1455-1463.
35.
Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med. 1995;333:201-205.
36.
Dube L, Granry JC. The therapeutic use of magnesium in anesthesiology, intensive care and emergency medicine: a review. Can J Anesth. 2003;50:732-746.
37.
Duley L, Henderson-Smart D.Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev. 2002;(3):CD000127.
38.
Duley L, Henderson-Smart D.Magnesium sulphate versus diazepam for eclampsia. Cochrane Database Syst Rev. 2002;(2):CD000127.
39.
Pritchard JA. The use of magnesium ion in the management of eclamptogenic toxemias. Surg Gynecol Obstet. 1955;100:131-140.
40.
Zuspan FP. Treatment of severe pre-eclampsia and eclampsia. Clin Obstet Gynecol. 1966;9:945-972.
41.
Connery LE, Coursin DB. Assessment and therapy of selected endocrine disorders. Anesthesiol Clin North Am. 2004;22(1):93-123.
42.
Vaughn ED. Diseases of the adrenal gland. Med Clin North Am. 2004;88:443-446.
43.
Dluhy RG, Lawrence JE, Williams GH. Endocrine hypertension. In: Williams RH, Larsen RP, Kronenberg HM, Melmed S, Polonsky KS, Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 10th ed.Philadelphia, Pa: Saunders; 2003. Elsevier.
44.
Noshiro T, Shimizu K, Watanabe T, et al.Changes in clinical features and long-term prognosis in patients with pheochromocytoma. Am J Hypertens. 2000;13:35-43.
45.
Kudva Y, Sawka A, Young W.The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab. 2003;88:4533-4539.
46.
Lenders JW, Pacak K, Walther MM, et al.Biochemical diagnosis in pheochromocytoma: which test is best?J Am Med Assoc. 2002;287:1427-1434.
47.
Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G.Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001;86:1480-1486.
48.
Boutros A, Bravo E, Zanettin G, Straffon R.Perioperative management of 63 patients with pheochromocytoma. Cleve Clin J Med. 1990:57:613-617.
49.
Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002;26:1037-1042.
50.
Miura Y, Yoshinaga K.Doxazosin: a newly developed, selective α1 -inhibitor in the management of patients with pheochromocytoma. Am Heart J. 1988;116:1785-1789.
51.
Kocak S, Aydintug S, Canakci N.α-blockade in preoperative preparation of patients with pheochromocytomas. Int Surg. 2002;87:191-194.
52.
Proye C, Thevenin D, Cecat P, et al.Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery. 1989;106:1149-1154.
53.
Prys-Roberts C.Phaeochromocytoma: recent progress in its management. Br J Anaesth. 2000;85:44-57.
54.
Vidt DG. Emergency room management of hypertensive urgencies and emergencies. J Clin Hypertens. 2001;3:158-164.
55.
Devlin J, Seta M, Salmaan K, et al.Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. Ann Pharmacother. 2004;38:755-759.
56.
Wilson DJ, Wallin JD, Vlachakis ND, et al.Intravenous labetalol in the treatment of severe hypertension and hypertensive emergencies. Am J Med. 1983;75(4A):95-102.
57.
Lebel M, Langlois S, Belleau LJ, Grose JH. Labetalol infusions in hypertensive emergencies. Clin Pharmacol Ther. 1985;37:615-618.
58.
Cruise CJ, Skrobik Y, Webster RE, Marquez-Julio A, David T.Intravenous labetalol versus sodium nitroprusside for treatment of hypertension post coronary bypass surgery. Anesthesiology. 1989;71:835-839.
59.
Atkin A, Jaker M, Beaty P, et al.Oral labetalol versus oral clonidine in the emergency treatment of severe hypertension. Am J Med Sci. 1992;303(1):9-15.
60.
Powers WJ, Zazulia AR, Videen TO, et al.Autoregulation of cerebral blood flow surrounding acute intracerebral hemorrhage. Neurology. 2001;57:18-24.
61.
Neutel J, Smith D, Wallin D, et al.A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension. Am J Hypertens. 1994;7:623-628.
62.
van Harten J, Burggraaf K, Danhof M, van Brummelen P, Breimer DD. Negligible sublingual absorption of nifedipine. Lancet. 1987;2:1363-1365.
63.
Schmetterer L, Wolzt M, Krejcy K, et al.Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model. Clin Pharmacol Ther. 1996;60:199-205.
64.
Schulz V, Loeschcke G.Hypotensive efficacy of a mixed solution of 0.1% sodium nitroprusside and 1% sodium thiosulphate. J Hypertens. 1985;3:485-489
65.
Cottrell JE, Casthely P, Brodie JD, et al.Prevention of nitroprusside-induced cyanide toxicity with hydroxycobalamin. N Engl J Med. 1978;298:809-811.
66.
Zerbe NF, Wagner BK. Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity. Crit Care Med. 1993;21:465-467.
